Veozah FDA-approved menopause drug to treat hot flashes

  • The Food and Drug Administration has approved Veozah (fezolinetant), a medication to treat menopausal symptoms.
  • The drug, produced by Tokyo-based Astellas Pharma, significantly reduces the hot flashes and night sweats that accompany menopause.
  • Veozah is considered a major development for menopause treatment because hormone therapy is not feasible for all patients.

The Food and Drug Administration has approved a once-daily pill to deal with uncomfortable hot flashes brought on by menopause.

The new drug, Veozah (fezolinetant), differs from the traditional treatment of increasing the hormones estrogen and progesterone to reduce menopausal symptoms, which include sweating, flushing and chills. Developed by Astellas Pharma, Veozah blocks a chemical in the brain called neurokinin B (NKB), which regulates body temperature.

“Hot flashes as a result of menopause can be a serious physical burden for women and affect their quality of life,” Janet Maynard, director of the FDA’s Office of Rare Diseases, Pediatrics, Urologic, and Reproductive Medicine, said in a statement. “The introduction of a new molecule to treat moderate to severe menopausal hot flashes will provide an additional safe and effective treatment option for women.”

Veozah FDA-approved menopause drug to treat hot flashes

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top